Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M402212200 on March 19, 2004

J. Biol. Chem., Vol. 279, Issue 20, 21431-21438, May 14, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/20/21431    most recent
M402212200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liz, M. A.
Right arrow Articles by Sousa, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liz, M. A.
Right arrow Articles by Sousa, M. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Transthyretin, a New Cryptic Protease*

Márcia Almeida Liz{ddagger}§, Carlos José Faro||, Maria João Saraiva{ddagger}§, and Mónica Mendes Sousa{ddagger}**

From the {ddagger}Molecular Neurobiology, Instituto de Biologia Molecular e Celular, 4150-180 Porto, Portugal, the ||Centro de Neurociências de Coimbra, 3004-517 Coimbra, Portugal, and the §Instituto de Ciências Biomêdicas Abel Salazar (ICBAS), Universidade do Porto, 4099-003 Porto, Portugal

Transthyretin (TTR) is a plasma homotetrameric protein that acts physiologically as a transporter of thyroxine (T4) and retinol, in the latter case through binding to retinol-binding protein (RBP). A fraction of plasma TTR is carried in high density lipoproteins by binding to apolipoprotein AI (apoA-I). We further investigated the nature of the TTR-apoA-I interaction and found that TTR from different sources (recombinant and plasmatic) is able to process proteolytically apoA-I, cleaving its C terminus after Phe-225. TTR-mediated proteolysis was inhibited by serine protease inhibitors (phenylmethanesulfonyl fluoride, Pefabloc, diisopropyl fluorophosphate, chymostatin, and N{alpha}-p-tosyl-L-phenylala-nine-chloromethyl ketone), suggesting a chymotrypsin-like activity. A fluorogenic substrate corresponding to an apoA-I fragment encompassing amino acid residues 223-228 (Abz-ESFKVS-EDDnp) was used to characterize the catalytic activity of TTR, including optimum reaction conditions (37 °C and pH 6.8) and catalytic constant (Km = 29 µM); when complexed with RBP, TTR activity was lost, whereas when complexed with T4, only a slight decrease was observed. Cell lines expressing TTR were able to degrade Abz-ESFKVS-EDDnp 2-fold more efficiently than control cells lacking TTR expression; this effect was reversed by the presence of RBP in cell culture media, therefore proving a TTR-specific proteolytic activity. TTR can act as a novel plasma cryptic protease and might have a new, potentially important role under physiological and/or pathological conditions.


Received for publication, February 27, 2004 , and in revised form, March 17, 2004.

* This project was supported by Fundação para a Ciência e Tecnologia (FCT) of Portugal. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Recipient of a fellowship (PRAXIS XXI/38247/BCI/2001) from Fundação para a Ciência e Tecnologia of Portugal.

** To whom correspondence should be addressed: Molecular Neurobiology Group, Inst. de Biologia Molecular e Celular, Rua Campo Alegre 823, 4150-180 Porto, Portugal. Tel.: 351-22-6074900; Fax: 351-22-6099157; E-mail: msousa{at}ibmc.up.pt.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Neurosci.Home page
C. E. Fleming, F. M. Mar, F. Franquinho, M. J. Saraiva, and M. M. Sousa
Transthyretin Internalization by Sensory Neurons Is Megalin Mediated and Necessary for Its Neuritogenic Activity
J. Neurosci., March 11, 2009; 29(10): 3220 - 3232.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
M. A. Liz, C. M. Gomes, M. J. Saraiva, and M. M. Sousa
ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity
J. Lipid Res., November 1, 2007; 48(11): 2385 - 2395.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
J C Sousa, G M. de Escobar, P Oliveira, M J Saraiva, and J A Palha
Transthyretin is not necessary for thyroid hormone metabolism in conditions of increased hormone demand
J. Endocrinol., November 1, 2005; 187(2): 257 - 266.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement